The company maintains a stable equity base of $129.6 million as of 2026Q1, though goodwill accounts for 42% of total assets, posing a risk of future impairment.
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 |
|---|
| Total Current Assets | 56.16M | 64.72M | 53.97M | 54.33M | 98.58M | 115.11M | 32.86M | 27.14M | 15.96M | 8.81M | 10.18M | 11.13M | 5.58M | 2.7M | 969.22K | 1.55M | 2.08M | 678.95K | 2.51M | 137.43K |
| Cash & Short-Term Investments | 20.17M | 23.36M | 13.38M | 13.85M | 74.14M | 84.68M | 10.52M | 18.85M | 8.91M | 5.12M | 7.03M | 8.21M | 3.45M | 1.12M | 284.26K | 959.17K | 1.28M | 656.39K | 2.5M | 135.43K |
| Cash Only | 20.17M | 23.36M | 13.38M | 13.85M | 18.21M | 84.68M | 10.52M | 18.85M | 8.91M | 5.12M | 7.03M | 8.21M | 3.45M | 1.12M | 284.26K | 959.17K | 1.28M | 656.39K | 2.5M | 135.43K |
| Short-Term Investments | 0 | 0 | 0 | 0 | 55.93M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 32.86M | 37.75M | 38.21M | 37.29M | 22.16M | 24.8M | 17.89M | 7.42M | 6.46M | 3.43M | 3.06M | 2.85M | 2.1M | 1.57M | 616.8K | 471.87K | 726K | 14.46K | 1.35K | 0 |
| Days Sales Outstanding | 116.46 | 125.92 | 151.39 | 190.3 | 129.49 | 147.69 | 150.72 | 110.07 | 111.15 | 103.26 | 144.11 | 143.94 | 117.89 | 115.38 | 109.89 | 154.95 | 3.73K | 197.57 | 5.87 | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 80.05K | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | - | - | - | - | - |
| Other Current Assets | 0 | 752K | 387K | 404.47K | 473.65K | 608.15K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Non-Current Assets | 111.1M | 112.2M | 117.2M | 129.04M | 36.07M | 25.87M | 27.47M | 29.5M | 9.09M | 954.85K | 1.3M | 1.19M | 1.45M | 1.31M | 1.21M | 1.34M | 1.66M | 211.19K | 136.01K | 157.54K |
| Property, Plant & Equipment | 459K | 510K | 516K | 722.3K | 372.77K | 472.64K | 594.83K | 735.88K | 149.33K | 167.31K | 173.65K | 10.24K | 12.81K | 15.06K | 20.68K | 23.93K | 13.06K | 13.58K | 15.27K | 5.97K |
| Fixed Asset Turnover | 192.46x | 214.57x | 178.54x | 99.02x | 167.53x | 129.68x | 72.82x | 33.43x | 142.01x | 72.49x | 44.64x | 705.21x | 507.53x | 329.22x | 99.04x | 46.45x | 5.44x | 1.97x | 5.48x | 16.80x |
| Goodwill | 70.87M | 70.87M | 70.87M | 78.36M | 22.67M | 14.74M | 14.74M | 14.74M | 3.68M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 39.75M | 40.8M | 45.52M | 49.4M | 13.02M | 10.65M | 12.12M | 13.94M | 5.26M | 782.5K | 1.12M | 1.17M | 1.44M | 1.29M | 1.18M | 1.31M | 1.23M | 197.61K | 120.74K | 151.56K |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 18K | 28K | 296K | 568.05K | 5.05K | 12.86K | 12.86K | 80.73K | 5.05K | 5.05K | 5.05K | 5.05K | 5.05K | 5.05K | 5.05K | 5.05K | 416.67K | 0 | 0 | 0 |
| Total Assets | 167.26M | 176.92M | 171.17M | 183.37M | 134.65M | 140.99M | 60.33M | 56.64M | 25.05M | 9.76M | 11.48M | 12.31M | 7.03M | 4.01M | 2.18M | 2.89M | 3.75M | 890.14K | 2.64M | 294.96K |
| Asset Turnover | 0.63x | 0.62x | 0.54x | 0.39x | 0.46x | 0.43x | 0.72x | 0.43x | 0.85x | 1.24x | 0.68x | 0.59x | 0.93x | 1.24x | 0.94x | 0.38x | 0.02x | 0.03x | 0.03x | 0.34x |
| Asset Growth % | 4.07% | 3.36% | -6.66% | 36.18% | -4.49% | 133.7% | 6.51% | 126.06% | 156.61% | -14.94% | -6.78% | 75.2% | 75.37% | 84.24% | -24.79% | -22.84% | 321.13% | -66.32% | 796.14% | - |
| Total Current Liabilities | 10.46M | 21.26M | 18.65M | 17.88M | 8.4M | 9.37M | 10.03M | 6.11M | 4.23M | 3.54M | 3.67M | 3.37M | 2.42M | 1.97M | 679.95K | 1.3M | 854.83K | 37.83K | 217.8K | 339.89K |
| Accounts Payable | 3.07M | 1.64M | 2.16M | 2.23M | 1.55M | 606.81K | 618.25K | 493K | 411.01K | 457.29K | 369.21K | 3.14M | 2.27M | 758.74K | 624.69K | 336.71K | 608.41K | 33.22K | 171.86K | 43.22K |
| Days Payables Outstanding | 23.95 | 14.87 | 24.03 | 28.4 | 24.09 | 8.63 | 11.75 | 19.65 | 16.67 | 27.03 | 39.5 | 316.19 | 257.55 | 156.69 | 1.98K | - | - | 4.58 | - | - |
| Short-Term Debt | 2.18M | 4.45M | 2M | 2M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4K | 277.75K |
| Deferred Revenue (Current) | 1.66M | 503K | 473K | 171.84K | 164.31K | 1.39M | 285.8K | 580.01K | 610.63K | 507.16K | 386.58K | 227K | 120.13K | 4.25K | 49.25K | 330.61K | 225.72K | 0 | -4K | -277.75K |
| Other Current Liabilities | 4.55M | 14.68M | 0 | 5.55M | 0 | 0 | 0 | 0 | 1.91M | 0 | 0 | 0 | 0 | -582K | 0 | 570K | 0 | 0 | 0 | 0 |
| Current Ratio | 5.37x | 3.04x | 2.89x | 3.04x | 11.74x | 12.29x | 3.28x | 4.44x | 3.77x | 2.49x | 2.78x | 3.30x | 2.31x | 1.37x | 1.43x | 1.19x | 2.44x | 17.95x | 11.51x | 0.40x |
| Quick Ratio | 5.37x | 3.04x | 2.89x | 3.04x | 11.74x | 12.29x | 3.28x | 4.44x | 3.77x | 2.49x | 2.78x | 3.30x | 2.31x | 1.37x | 1.43x | 1.19x | 2.34x | 17.95x | 11.51x | 0.40x |
| Cash Conversion Cycle | 92.51 | - | - | - | - | - | - | - | - | - | - | - | - | -41.31 | - | - | - | - | - | - |
| Total Non-Current Liabilities | 27.19M | 27.36M | 35.52M | 38.94M | 144.53K | 236.73K | 325.53K | 5.67M | 2.37M | 2.58M | 2.91M | 0 | 2.1M | 1.78M | 576K | 0 | 1M | 0 | 0 | 50K |
| Long-Term Debt | 21.34M | 21.42M | 30.82M | 34.23M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 50K |
| Capital Lease Obligations | 1.07M | 234K | 209K | 371.44K | 144.53K | 236.73K | 325.53K | 448.75K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 14.82M | 5.71M | 4.49M | 4.34M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.22M | 2.37M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1M | 0 | 0 | 0 |
| Total Liabilities | 37.65M | 48.62M | 54.17M | 56.82M | 8.54M | 9.61M | 10.35M | 11.78M | 6.6M | 3.54M | 3.67M | 3.37M | 2.42M | 1.97M | 679.95K | 1.3M | 1.85M | 37.83K | 217.8K | 389.89K |
| Total Debt | 23.72M | 26.1M | 33.19M | 36.82M | 234.43K | 327.71K | 448.75K | 564.18K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4K | 327.75K |
| Net Debt | 3.55M | 2.74M | 19.81M | 22.97M | -17.97M | -84.35M | -10.07M | -18.29M | -8.91M | -5.12M | -7.03M | -8.21M | -3.45M | -1.12M | -284.26K | -959.17K | -1.28M | -656.39K | -2.5M | 192.32K |
| Debt / Equity | 0.18x | 0.20x | 0.28x | 0.29x | 0.00x | 0.00x | 0.01x | 0.01x | - | - | - | - | - | - | - | - | - | - | 0.00x | - |
| Debt / EBITDA | 1.27x | 1.59x | - | - | - | 0.14x | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | 0.19x | 0.17x | - | - | - | -36.26x | - | - | -17.95x | - | - | - | - | -2.73x | - | - | - | - | - | - |
| Interest Coverage | 2.84x | 2.28x | -2.15x | -16.31x | - | - | - | - | - | - | - | - | - | - | -4544.53x | -1.21x | -17.86x | -4409.15x | -6952.93x | -64.42x |
| Total Equity | 129.61M | 128.29M | 117M | 126.55M | 126.11M | 131.38M | 49.97M | 44.86M | 18.46M | 6.22M | 7.81M | 8.94M | 4.61M | 2.04M | 1.5M | 1.59M | 1.89M | 852.31K | 2.43M | -94.93K |
| Equity Growth % | 26.51% | 9.65% | -7.55% | 0.35% | -4.01% | 162.9% | 11.39% | 143.04% | 196.73% | -20.37% | -12.64% | 93.98% | 126.05% | 36.37% | -5.9% | -16.09% | 122.2% | -64.86% | 2655.13% | - |
| Book Value per Share | 6.91 | 6.75 | 6.40 | 7.39 | 7.09 | 7.43 | 3.37 | 3.35 | 1.56 | 0.63 | 0.79 | 1.09 | 0.62 | 0.29 | 0.32 | 0.34 | 0.43 | 0.20 | 0.61 | -0.03 |
| Total Shareholders' Equity | 129.61M | 128.29M | 117M | 126.55M | 126.11M | 131.38M | 49.97M | 44.86M | 18.46M | 6.22M | 7.81M | 8.94M | 4.61M | 2.04M | 1.5M | 1.59M | 1.89M | 852.31K | 2.43M | -94.93K |
| Common Stock | 21K | 20K | 20K | 19.9K | 18.29K | 17.86K | 15.22K | 14.6K | 12.04K | 29.32K | 29.72K | 29.03K | 22.87K | 14.77K | 14.23K | 14.19K | 13.61K | 12.83K | 12.26K | 10.3K |
| Retained Earnings | -79.73M | -79.24M | -84.37M | -64.26M | -46.69M | -35.25M | -35.63M | -33.42M | -30.28M | -30.36M | -28.26M | -26.72M | -26.12M | -24.62M | -24.74M | -24.38M | -21.76M | -19.05M | -14.49M | -394.93K |
| Treasury Stock | -2K | -2K | -2K | -1.74K | -1.21K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -104.7K | -74.28K | -25.69K | -22.41K | -17.79K | -18.39K | -12.76K | -7.29K | -5.06K | -3.31K | -1.62K | -295 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EHR partner dependency risk
According to recent quarterly filings, OptimizeRx has maintained a relatively stable equity base of approximately $129.6 million as of 2026Q1, though the persistent negative retained earnings of $79.7 million suggest that historical capital allocation has yet to translate into sustained, profitable growth for shareholders.
The company's trajectory appears to be in a consolidation phase, where the balance sheet is supported by equity rather than operational earnings. Investors should monitor whether the recent stabilization in total assets indicates a shift toward more disciplined capital deployment or merely a pause in acquisition-led expansion.
Based on reported financial statements, OPRX has successfully reduced its total debt from $36.8 million in 2023Q4 to $23.7 million by 2026Q1, reflecting a deliberate effort to deleverage the balance sheet despite the inherent volatility of its campaign-based revenue model and ongoing operational cash flow challenges.
While the reduction in debt improves the D/E ratio to 0.18, the reliance on external financing to fund past growth remains a point of concern. The company's ability to manage these obligations without further dilution or cash strain warrants close observation as it navigates its transition to higher-margin data products.
As indicated by the 2026Q1 data, the company maintains a current ratio of 5.37, which suggests a strong short-term liquidity position; however, this figure is heavily influenced by the timing of working capital cycles rather than a consistent accumulation of excess cash reserves for future investment.
The liquidity buffer appears adequate to cover immediate operational needs, yet the fluctuation in cash balances—ranging from $13.4 million to $23.4 million over the last ten quarters—highlights the sensitivity of the firm's cash position to the lumpy nature of pharmaceutical marketing campaign collections. This volatility suggests that the company may remain vulnerable to sudden shifts in partner payment terms.
Based on the provided balance sheet data, goodwill remains a significant component of total assets at $70.9 million, representing over 42% of the total asset base as of 2026Q1, which introduces a non-trivial risk of future impairment charges if acquisition synergies fail to materialize as expected.
The concentration of value in intangible assets suggests that the company's reported book value may be sensitive to the long-term success of its data-targeting integrations. Investors should be wary that any failure to achieve projected growth from these acquisitions could necessitate a write-down, further pressuring the already strained retained earnings position.
Quick answers to the most common questions about buying OPRX stock.
As of 2025, OptimizeRx Corporation (OPRX) had total assets of $176.9M including $64.7M in current assets.
OptimizeRx Corporation (OPRX) carries total debt of $26.1M, offset by $23.4M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
OptimizeRx Corporation (OPRX) has total shareholders' equity (book value) of $128.3M ($6.75 book value per share). Book value represents the net worth of the company belonging to common stock holders.
OptimizeRx Corporation (OPRX) reported a current ratio of 3.04x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.